This is consistent with in vivo studies illustrating that VEGF expression in GISTs might be a predictive factor for early treatment failure and poor survival of GIST patients on IM-based therapy, regardless of KIT genotype [44,46]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.